U.S. Markets closed

Can-Fite BioPharma Ltd. (CANF)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
1.72-0.01 (-0.58%)
At close: 3:58PM EDT
People also watch
VBLTCNATBLRXWGBSAQXP
Full screen
Previous Close1.73
Open1.71
Bid0.00 x 0
Ask0.00 x 0
Day's Range1.71 - 1.72
52 Week Range1.50 - 2.79
Volume5,576
Avg. Volume30,007
Market Cap27.21M
Beta0.81
PE Ratio (TTM)-3.51
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research7 months ago

    CANF: Ready to Start Two Phase III Trials in 2017

    On Feb. 8, 2017, Can-Fite (CANF) announced through a news release that the Company is ready to commence patient enrollment in the 2Q17 in its global Phase III trial of its lead drug candidate Piclidenoson (CF101) as a first line treatment for rheumatoid arthritis (RA). The EMA suggested Piclidenoson should be developed as an alternative to MTX, the most widely prescribed rheumatoid arthritis drug in the world. The EMA further suggested that this pivotal Phase III study will serve as the first of two pivotal studies required for drug approval.

  • Investopedia11 months ago

    Can-Fite Submits Protocol for NAFLD/NASH CF102 Drug (CANF)

    Targeting an estimated $35 billion market by 2025, Can-Fite submits a clinical trial protocol for its Phase II study of the drug

  • We're sorry this is all we were able to find about this topic.